Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
ozanimod
|
| gptkbp:administrativeDivision |
once daily
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
Phase 3
relapsing forms of multiple sclerosis RADIANCE SUNBEAM included_in_MS_treatment_guidelines |
| gptkbp:contraindication |
gptkb:pulmonary_embolism
hypertension anaphylaxis bradycardia active infection macular edema liver impairment |
| gptkbp:date |
March 2020
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
CYP3A4 inducers
high bioavailability CYP2C8 inhibitors metabolized by CYP enzymes |
| gptkbp:formulation |
delayed-release
|
| gptkbp:hasCapacity |
available through manufacturer programs
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zeposia
|
| gptkbp:label |
black box warning
|
| gptkbp:lastProduced |
2020
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketedAs |
gptkb:Zeposia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by insurance
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:pressBox |
risk of fetal harm
risk of infections risk of liver injury |
| gptkbp:research |
public and private sectors
|
| gptkbp:researchAreas |
neurology
autoimmune diseases |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
liver function tests
complete blood count |
| gptkbp:sideEffect |
headache
infections elevated liver enzymes |
| gptkbp:skills |
0.92 mg
|
| gptkbp:triggerType |
sphingosine 1-phosphate receptor modulator
|
| gptkbp:usedFor |
multiple sclerosis
|